Köhler, Michael

[["dc.bibliographiccitation.firstpage","109"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","112"],["dc.bibliographiccitation.volume","80"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T09:23:01Z"],["dc.date.available","2018-11-07T09:23:01Z"],["dc.date.issued","2001"],["dc.description.abstract","Transplantation of peripheral blood stem cells (PBSC), positively and/or negatively selected immediately after harvest, has become a widely applied therapeutic option in hematological or oncological patients. The following case of peripheral blood stem cell transplantation represents the first case of successful transplantation of PBSC, cryopreserved twice and purged after cryopreservation. PBSC were harvested in a 44-year-old female patient with a low-grade non-Hodgkin's lymphoma stage IV after mobilization with chemotherapy and G-CSF. A total number of 15.2 x 10(6) CD34(+) cells/kg bodyweight was harvested with a 36.9% contamination of tumor cells coexpressing CD5 and CD20. After subsequent chemotherapy cycles and cyclophosphamide mobilization, only 0.77 x 10(6) CD34(+) cells/kg bodyweight, not sufficient for transplantation, were achieved after positive selection. Therefore, 10.8 x 10(6) cryopreserved CD34(+) cells/kg bodyweight were thawed and a positive selection was carried out with the BAXTER Isolex 300i machine. Before additional negative selection, the 0.77 x 10(6) positively selected CD34(+) cells/kg bodyweight from the second mobilization were added. A total quantity of 4.4 x 10(6) CD34(+) cells/kg bodyweight with a purity of 93.1% representing a recovery of 38% was obtained. Cells were again cryopreserved, stored and retransfused after conditioning the patient with TBI and high-dose cyclophosphamide. The patient engrafted with a WBC count >1000/mul on day eight and a platelet count > 20,000/mul without transfusion support on day 12 post-transplantation. This case indicates that purging procedures can successfully be carried out with cryopreserved cell material and that purified CD34(+) cells can be cryopreserved a second time before transplantation, without affecting their hematopoietic capacity."],["dc.identifier.doi","10.1007/s002770000243"],["dc.identifier.isi","000167191200010"],["dc.identifier.pmid","11261320"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29482"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.title","Successful transplantation and engraftment of peripheral blood stem cells after cryopreservation, positive and negative purging procedures, and a second cryopreservation cycle"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","109"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Apheresis"],["dc.bibliographiccitation.lastpage","113"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Koch, S."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Munzel, U."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T09:34:58Z"],["dc.date.available","2018-11-07T09:34:58Z"],["dc.date.issued","2001"],["dc.description.abstract","Some data exist on the influence of leukapheresis volume on the number of harvested peripheral blood hematopoietic progenitor cells (HPC), but less is known about the influence on the composition of HPC. We therefore performed a prospective, randomized crossover trial to evaluate the effect of large-volume (LVL) vs. normal-volume leukapheresis (NVL) on subpopulations of CD34(+) cells in the harvest product of 15 patients with breast cancer and 8 patients with non-Hodgkin's lymphoma. Patients were randomly assigned to start either with an LVL on day 1 followed by an NVL on day 2 or vice versa. The number of HPC; the extraction efficiency defined as difference between yield in the harvest and decrease in peripheral blood, and the relative proportion as well as the absolute numbers of CD34(+) cells coexpressing CD38, CD90, HLA-DR, CD117, CD7, CD19, CD41, or CD33 were evaluated. There was no significant difference with regard to the percentages of the subsets on comparison of LVL to NVL procedures. Only the absolute median number of CD34(+)HLA-DR- cells was significantly (P=0.02) higher in LVL harvests compared with the corresponding NVL components; which can be explained on the basis of the higher yield and the higher extraction efficiency in LVL compared with NVL. LVL results in a higher yield of CD34(+) cells and leads to an intra-apheresis recruitment of HPC but the relative composition of the harvested CD34(+) cells is not changed significantly. In addition, the amount of early, HLA-DR-, hematopoietic HPC seems to be increased by an LVL. (C) 2001 Wiley-Liss, Inc."],["dc.identifier.isi","000171650400001"],["dc.identifier.pmid","11746535"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32289"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0733-2459"],["dc.title","Prospective, randomized, sequential, crossover trial of large-volume vs. normal-volume leukapheresis procedures: Effects on subpopulations of CD34(+) cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","830"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","831"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Koehler, M."],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Mayr, Wolfgang R."],["dc.contributor.author","Schwartz, DWM"],["dc.contributor.author","Heermann, K. H."],["dc.date.accessioned","2018-11-07T10:38:50Z"],["dc.date.available","2018-11-07T10:38:50Z"],["dc.date.issued","2003"],["dc.identifier.doi","10.1046/j.1537-2995.2003.00409.x"],["dc.identifier.isi","000183119000025"],["dc.identifier.pmid","12757539"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45903"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","Risk of transfusion-transmitted infections by NAT-negative blood"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1363"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","1370"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Kurz, M."],["dc.contributor.author","Eil, A."],["dc.contributor.author","Storkebaum, B."],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Munzel, U."],["dc.contributor.author","Funke, I."],["dc.contributor.author","Hocker, P."],["dc.contributor.author","Wiesneth, M."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T08:55:02Z"],["dc.date.available","2018-11-07T08:55:02Z"],["dc.date.issued","2000"],["dc.description.abstract","BACKGROUND: Mobilization and homing of PBPCs are still poorly understood. Thus, a sufficient algorithm for the prediction of PBPC yield in apheresis procedures does not yet exist. STUDY DESIGN AND METHODS: The decline of CD34+ cells in the peripheral blood during apheresis and their simultaneous increase in the collection bag were determined in a prospective study of 18 consecutive apheresis procedures. A cell-kinetic, four-compartment model describing these changes was developed. Retrospective data from 136 apheresis procedures served to further improve this model. A predictive algorithm for the yield was developed that considered the sex, weight, and height of the patient, the number of CD34+ cells in peripheral blood before apheresis, the inlet flow, and the duration of the apheresis. The accuracy of this algorithm was evaluated by comparison of the predicted and the observed yields of CD34+ cells in 105 prospective autologous and 148 retrospective allogeneic apheresis procedures. RESULTS: The correlation between predicted and observed yields was good for the autologous and allogeneic groups with a correlation coefficient (r) of 0.8979 and 0.8311 (p<0.0001), respectively. The regression is described by the equations log (measured value [m]) = 1.0118 + 0.8595 x log (predicted value [p]) for the autologous and log (m) = 2.226 + 0.7559 x log (p) for the allogeneic group. The respective equations for the zero-point regression are log (m)= 1.014 x log (p) and log (m) = 1.026 x log (p). The probability that the measured value was 90 percent or more of the predicted value was 83.8 percent for the autologous and 90.5 percent for the allogeneic apheresis procedures. CONCLUSION: The predictive accuracy of the algorithm and the slope of the zero-point regression curve were higher for allogeneic than autologous PBPC collections. The predictive algorithm may be a useful tool in PBPC harvest, enabling the adaptation of the size of the apheresis to the needs of each patient."],["dc.identifier.doi","10.1046/j.1537-2995.2000.40111363.x"],["dc.identifier.isi","000165492600013"],["dc.identifier.pmid","11099666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22808"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","A cell-kinetic model of CD34+cell mobilization and harvest: development of a predictive algorithm for CD34+cell yield in PBPC collections"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","263"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Vox Sanguinis"],["dc.bibliographiccitation.lastpage","265"],["dc.bibliographiccitation.volume","86"],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Koehler, M."],["dc.contributor.author","Maas, J. H."],["dc.contributor.author","Meyer, M."],["dc.contributor.author","Neumeyer, H."],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Riggert, Joachim"],["dc.date.accessioned","2018-11-07T10:49:32Z"],["dc.date.available","2018-11-07T10:49:32Z"],["dc.date.issued","2004"],["dc.identifier.doi","10.1111/j.0042-9007.2004.00486.x"],["dc.identifier.isi","000221402500007"],["dc.identifier.pmid","15144532"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48455"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Ltd"],["dc.relation.issn","0042-9007"],["dc.title","Rhabdomyolysis in allogeneic peripheral blood stem cell donors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","784"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","788"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Nubling, C. M."],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Unger, G."],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Heermann, K. H."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T08:54:09Z"],["dc.date.available","2018-11-07T08:54:09Z"],["dc.date.issued","2000"],["dc.description.abstract","In 1994, quarantine fresh-frozen plasma (Q-FFP) was introduced in Germany in order to reduce the risk of HIV and HCV transmission In 1998, an acute HCV infection of a patient was reported to us. The look-back revealed that this patient had received two Q-FFP from a donor who had seroconverted for HCV in the meantime. Recipients of further plasma donations from this donor were identified. Back-up specimens of these donations were investigated in several laboratories. A total of 25 additional HCV-PCR positive plasma units had been transfused to 12 further patients. HCV infections were diagnosed in seven of these recipients, three patients had already been deceased. One of the remaining two recipients was already HCV positive prior to transfusion, in the other patient, no HCV infection was detectable. This patient had received three units of an \"early\" plasma donation, which was tested negative by PCR in one laboratory, but positive in the other. The subsequent, clinically infectious donation had the same discrepant PCR results. Thus, eight cases of HCV transmission were revealed and classified as \"certain\" with regard to causality, also due to an identical HCV genotype, i.e. 3e. Some of these infections would have been prevented by application of a different anti-HCV assay. The assay used in the respective plasmapheresis station was in-sensitive in this individual case for more than 400 days after the first PCR positive donation. This caused the release of the above mentioned infectious units. Upon re-testing the backups, three of four other anti-HCV assays revealed a positive result already 104 days after the first PCR-positive donation. The donor had increased ALAT levels (> 23 IU/L) at nine of 28 donations, two of these were higher than 2.5 times the upper normal limit, and two were higher than 68 IU/L, which is the cut-off value for male blood donors in Germany. The results of these (look-back) studies arouse several queries, i.e, differences in the diagnostic sensitivity between current anti-HCV and PCR tests, the accuracy of risk-estimates (especially when based on hemovigilance studies for Q-FFP), the value of ALAT testing, and currently practised release algorithms for Q-FFP."],["dc.identifier.isi","000165403900010"],["dc.identifier.pmid","11127856"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22607"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","F K Schattauer Verlag Gmbh"],["dc.relation.issn","0340-6245"],["dc.title","Hepatitis C virus transmission through quarantine fresh-frozen plasma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1192"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","1197"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Simson, G."],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Munzel, U."],["dc.contributor.author","Uy, Angela"],["dc.contributor.author","Kohler, M."],["dc.contributor.author","Heermann, K. H."],["dc.date.accessioned","2018-11-07T10:01:05Z"],["dc.date.available","2018-11-07T10:01:05Z"],["dc.date.issued","2000"],["dc.description.abstract","BACKGROUND: To allow cost-effective RNA testing with NAT techniques, the national authorities of several countries have planned or already introduced tests of mixed specimens, that is, plasma pools. STUDY DESIGN AND METHODS: High-throughput extraction, amplification, and detection of HCV RNA from individual blood donations were optimized and validated. The feasibility of the method and the frequency of anti-HCV-negative, HCV RNA-positive donations were determined in a prospective study of 27,745 allogeneic and 792 autologous individual donations. RESULTS: The 50- and 95-percent detection limits of the method were determined at 44 IU per mt and 162 IU per mt, respectively (World Health Organization HCV reference material). When 201 HCV RNA-positive sera were taken as a reference, the sensitivity was 97.5 percent. The assay specificity was determined at 99.77 percent. During a 20-month period, two seronegative blood donors tested positive in HCV PCR. The viral load of these donations was 6 x 10(6) and 3 x 10(7) copies per mL, respectively. Thus, the yield of HCV RNA testing in this study was 7.63 per 100,000 screened donations (95% CI, 1.25-22.07). In both PCR-positive donors, seroconversion was found in subsequent blood samples. CONCLUSION: This study compares the feasibility of single-donation HCV RNA screening, with the detection of a relatively high percentage of window-phase donations, to data reported from groups using HCV RNA testing of plasma pools. The relative yield of NAT of individual donations versus minipools should be directly investigated in the near future."],["dc.identifier.doi","10.1046/j.1537-2995.2000.40101192.x"],["dc.identifier.isi","000089844200009"],["dc.identifier.pmid","11061854"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37942"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","82"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","86"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Simson, G."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T09:40:11Z"],["dc.date.available","2018-11-07T09:40:11Z"],["dc.date.issued","2001"],["dc.description.abstract","BACKGROUND: Virus inactivation of plasma can be achieved by photodynamic methods in the presence of phenothiazine dyes such as methylene blue (MB). Subsequent filtration may increase the efficacy of virus inactivation and reduce adverse effects of WBC contamination and MB. STUDY DESIGN AND METHODS: This study examined the effect of filtration with three different filters (MBF1, MBF2, and MBF3) on MB concentration, residual cells, coagulation factors, and activation measures of coagulation, fibrinolysis, and complement in MB-treated (1 muM/L) plasma units. RESULTS: Filtration reduced the concentration of MB by greater than or equal to 89 percent. WBCs were depleted by 92 percent (MBF1) and >99.9 percent (MBF2 and MBF3). Treatment with MB significantly decreased the coagulation potency from levels in untreated plasma, as measured by thromboplastin time ratio (112 +/- 18% vs. 95 +/- 11%), activated partial thromboplastin time (40 +/- 3 sec vs. 44 +/- 3 sec), thrombin time (16.9 +/- 1.1 sec vs. 18.6 +/- 1.5 sec), factor VIII (1.09 +/- 0.21 U/mL vs. 0.85 +/- 0.13 U/ mt), and vWF (0.94 +/- 0.65 U/mL vs. 0.65 +/- 0.24 U/mL). Filtration did not further decrease these values, while factor XI (0.75 +/- 0.22 U/mL vs. 0.37 +/- 0.20 U/mL) and prekallikrein values decreased in MB plasma units filtered with the MBF3. In addition, activated factor XII (0.7 +/- 0.5 mug/L vs. 4.5 +/- 1.0 mug/L) increased. CONCLUSION: WBCs and MB can be eliminated from MB-treated plasma units by filtration. Differences in biocompatibility of the different filters, especially the influence on the contact phase of coagulation, must be taken into consideration."],["dc.identifier.doi","10.1046/j.1537-2995.2001.41010082.x"],["dc.identifier.isi","000166582400015"],["dc.identifier.pmid","11161250"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33452"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","368"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","374"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Munzel, U."],["dc.contributor.author","Kohler, M."],["dc.date.accessioned","2018-11-07T09:46:38Z"],["dc.date.available","2018-11-07T09:46:38Z"],["dc.date.issued","2000"],["dc.description.abstract","BACKGROUND: LVL procedures with the administration of heparin as an additional anticoagulant are increasingly performed because of the potentially higher yield of autologous peripheral blood HPCs. A prospective, randomized crossover trial was performed to evaluate the influence of leukapheresis volume-that is, large versus normal-on serum electrolytes, platelet count, and other coagulation measures in 25 patients with breast cancer and 14 patients with non-Hodgkin's lymphoma. STUDY DESIGN AND METHODS: Patients were randomly assigned to start either with an LVL on Day 1 followed by a normal-volume leukapheresis (NVL) on Day 2 or vice versa. In LVL, heparin was administered in addition to ACD-A. Bleeding complications, transfusion support, whole-blood counts, and several coagulation measures as well as plasma heparin levels were evaluated. RESULTS: Although the duration, the infused amount of ACD-A, the flow rate, the drop in platelet count, and the drop in potassium were significantly greater in LVL, and although LVL patients also received heparin, there was no significant difference in clinical tolerance or bleeding complications. After LVL, patients exhibited a significantly longer activated partial thromboplastin time (APTT), with a median of 70 seconds (range, 44-100 sec), and a median anti-factor Xa activity of 0.69 IU per mt (range, 0.10-1.29 IU/mL). The value of the APTT after LVL correlated with anti-factor Xa activity (r = 0.37, p<0.05), but not with platelet count or heparin infusion rate. Markers for coagulation activation did not increase during NVL or LVL. CONCLUSION: LVL with heparin as an additional anticoagulant seems to be a safe procedure in patients with low preleukapheresis platelet counts. No activation of coagulation occurred after NVL or LVL procedures."],["dc.identifier.doi","10.1046/j.1537-2995.2000.40030368.x"],["dc.identifier.isi","000086036200019"],["dc.identifier.pmid","10738041"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34923"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","A prospective, randomized, sequential crossover trial of large-volume versus normal-volume leukapheresis procedures: effects on serum electrolytes, platelet counts, and other coagulation measures"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]